AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35044445 — intervention group
Group type: EXPERIMENTAL
Intervention: Archetypal analysis (AA) applied to ON VFs
Number of subjects: 456
Study 35044445 — intervention group
Group type: COMPARATOR
Intervention: Control group VFs analyzed using AA
Number of subjects: 456
Study 35045174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome of adults with T1D
Number of subjects: 74
Study 35045174 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiome of healthy control subjects
Number of subjects: 74
Study 35045174 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional analysis of gut microbiome
Number of subjects: 74
Study 35045174 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial taxa and metabolic pathways
Number of subjects: 74
Study 35045184 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 686
Study 35045184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia and higher insulin doses
Number of subjects: 686
Study 35045184 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) adjusted for suPAR levels
Number of subjects: 686
Study 35045184 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) mediated by suPAR
Number of subjects: 686
Study 35045358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CAR T cells administered intrapleurally (10-186 mL) via image-guided techniques (intracavitary or intratumoral)
Number of subjects: 31
Study 35045358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CAR T cells administered intrapleurally
Number of subjects: 31
Study 35045389 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 25
Study 35045389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (SB)
Number of subjects: 25
Study 35045389 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental hypoglycemia worry
Number of subjects: 25
Study 35045421 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat (Isturisa®)
Number of subjects: 0
Study 35045559 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU cholecalciferol every 6 to 8 weeks
Number of subjects: 43
Study 35045559 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU cholecalciferol every 4 to 5 weeks
Number of subjects: 43
Study 35045732 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting distal coronary to aortic pressure ratio (Pd/Pa)
Number of subjects: 517
Study 35045732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 517
Study 35045732 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR and Pd/Pa discrepancy
Number of subjects: 517
Study 35045748 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35045815 — intervention group
Group type: EXPERIMENTAL
Intervention: Various palliative interventions for ESCC including chemotherapy, radiation therapy (with and without chemotherapy), and esophageal stenting with self-expandable metallic stents.
Number of subjects: 0
Study 35045843 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1388
Study 35045843 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor physical performance (lower SPPB values)
Number of subjects: 1388
Study 35045843 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved physical performance (higher SPPB values)
Number of subjects: 1388
Study 35045843 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPB values
Number of subjects: 1388
Study 35045843 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features and SPPB in multivariable model
Number of subjects: 1388
Study 35045877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, person-centered anticipatory care planning (ACP) intervention
Number of subjects: 12
Study 35045989 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg IV on day 0, followed by 100 mg IV daily for 10 days)
Number of subjects: 1282
Study 35045989 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1282
Study 35046010 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative semistructured interviews conducted 6-16 months after patient death
Number of subjects: 28
Study 35046010 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of family members during pandemic restrictions
Number of subjects: 28
Study 35046010 — intervention group
Group type: EXPERIMENTAL
Intervention: Solidarity among clinical staff
Number of subjects: 28
Study 35046010 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for improving end-of-life care
Number of subjects: 28
Study 35046056 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP152 monotherapy (30 mg, once-weekly intravenous infusion)
Number of subjects: 37
Study 35046059 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib and Pembrolizumab
Number of subjects: 29
Study 35046060 — intervention group
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DTPA-CHX-A"-SC16 at 500 μCi
Number of subjects: 18
Study 35046060 — intervention group
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DTPA-CHX-A"-SC16 at 750 μCi
Number of subjects: 18
Study 35046060 — intervention group
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DTPA-CHX-A"-SC16 at 250 μCi
Number of subjects: 18
Study 35046060 — intervention group
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DTPA-CHX-A"-SC16
Number of subjects: 18
Study 35046063 — intervention group
Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel
Number of subjects: 100
Study 35046093 — intervention group
Group type: EXPERIMENTAL
Intervention: CD therapeutic dietary intervention (CD-TDI)
Number of subjects: 102
Study 35046124 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 42
Study 35046124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac power output (CPO)
Number of subjects: 42
Study 35046124 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke work (SW)
Number of subjects: 42
Study 35046124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen delivery
Number of subjects: 42
Study 35046124 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory markers (lactate and venous-to-arterial carbon dioxide difference)
Number of subjects: 42
Study 35046124 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory and cardiac biomarkers
Number of subjects: 42
Study 35046132 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-sparing immunosuppressive protocol
Number of subjects: 97
Study 35046132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone histomorphometry
Number of subjects: 97
Study 35046132 — intervention group
Group type: COMPARATOR
Intervention: Control of mineral metabolism
Number of subjects: 97
Study 35046672 — intervention group
Group type: EXPERIMENTAL
Intervention: KPC-producing strains
Number of subjects: 36
Study 35046747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (five 30-minute weekly sessions)
Number of subjects: 108
Study 35046747 — intervention group
Group type: COMPARATOR
Intervention: Control group (sitting quietly during the experimental sessions)
Number of subjects: 108
Study 35046880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mannitol (18 g per day)
Number of subjects: 22
Study 35046880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 22
Study 35046943 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemoradiotherapy combined with PD-1 blockade
Number of subjects: 0
Study 35046943 — intervention group
Group type: EXPERIMENTAL
Intervention: High percentages of PD-L1
Number of subjects: 0
Study 35047011 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic gradient boosting model
Number of subjects: 394
Study 35047784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy after revascularisation
Number of subjects: 10000000
Study 35047784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis by gender and disease severity
Number of subjects: 10000000
Study 35047801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate artery embolization (PAE)
Number of subjects: 164
Study 35047801 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 164
Study 35048355 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of pemetrexed
Number of subjects: 0
Study 35048355 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of pemetrexed
Number of subjects: 0
Study 35048715 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 204
Study 35048715 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 204
Study 35048809 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Oxaliplatin Suspension for Injection (MBP-426)
Number of subjects: 0
Study 35048809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OxPt)
Number of subjects: 0
Study 35049375 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35049381 — intervention group
Group type: EXPERIMENTAL
Intervention: History of sexual assault
Number of subjects: 0
Study 35049381 — intervention group
Group type: COMPARATOR
Intervention: No history of sexual assault
Number of subjects: 0
Study 35050485 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 327
Study 35050485 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg
Number of subjects: 327
Study 35050743 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma T790M testing
Number of subjects: 63
Study 35050743 — intervention group
Group type: COMPARATOR
Intervention: Tissue T790M testing
Number of subjects: 63
Study 35050743 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib treatment
Number of subjects: 63
Study 35050753 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-based recommended therapy (MBRT)
Number of subjects: 50
Study 35050753 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies provided in the setting of a clinical trial or through compassionate use programs
Number of subjects: 50
Study 35050753 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study 35050780 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic SVI (gSVI) classifier
Number of subjects: 15889
Study 35050780 — intervention group
Group type: EXPERIMENTAL
Intervention: gSVI combined with MSKCC nomogram
Number of subjects: 15889
Study 35050780 — intervention group
Group type: COMPARATOR
Intervention: Established nomograms (Partin Tables and MSKCC)
Number of subjects: 15889
Study 35050961 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary multimodal pain therapy
Number of subjects: 41
Study 35051703 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cCRT) with trametinib (1.5 mg)
Number of subjects: 15
Study 35051737 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA
Number of subjects: 82
Study 35051737 — intervention group
Group type: EXPERIMENTAL
Intervention: OHS
Number of subjects: 82
Study 35051737 — intervention group
Group type: EXPERIMENTAL
Intervention: ORSH
Number of subjects: 82
Study 35051831 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding (gastrointestinal, intracranial, hematoma, genitourinary, retroperitoneal, other sites) during anticoagulation
Number of subjects: 2244
Study 35051831 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding in the first 30 days after VTE
Number of subjects: 2244
Study 35051950 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe intraoperative hyperglycemia (SIH) with blood glucose concentration (BGC) ≥180 mg/dL
Number of subjects: 514
Study 35051950 — intervention group
Group type: COMPARATOR
Intervention: No severe intraoperative hyperglycemia (BGC <180 mg/dL)
Number of subjects: 514
Study 35051950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative BGC >140 mg/dL
Number of subjects: 514
Study 35051950 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated preoperative glycated hemoglobin (HbA1c) concentration
Number of subjects: 514
Study 35056370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitoring
Number of subjects: 0
Study 35056370 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer Rating Scale
Number of subjects: 0
Study 35057743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lognormal shared frailty models with restricted cubic splines and non-proportional hazards (LSF-NPH)
Number of subjects: 0
Study 35057743 — intervention group
Group type: COMPARATOR
Intervention: Inverse Gaussian shared frailty model with proportional hazard (ISF-PH)
Number of subjects: 0
Study 35057807 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (at least 2 times/week to every day)
Number of subjects: 0
Study 35057807 — intervention group
Group type: COMPARATOR
Intervention: Lower exercise levels
Number of subjects: 0
Study 35057807 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 0
Study 35057807 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity in diabetic individuals
Number of subjects: 0
Study 35058267 — intervention group
Group type: EXPERIMENTAL
Intervention: Markerless tumour tracking (MTT)
Number of subjects: 30
Study 35058275 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-curative ESD followed by surgical treatment (n=126)
Number of subjects: 604
Study 35058275 — intervention group
Group type: COMPARATOR
Intervention: Non-curative ESD followed by endoscopic follow-up (n=81)
Number of subjects: 604
Study 35058326 — intervention group
Group type: EXPERIMENTAL
Intervention: isatuximab (anti-CD38 monoclonal antibody) + cemiplimab (anti-PD-1 monoclonal antibody)
Number of subjects: 44
Study 35058354 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA fraction (dd-cfDNA[%]) in plasma
Number of subjects: 289
Study 35058354 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide gene expression in biopsies
Number of subjects: 289
Study 35058354 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray-based Molecular Microscope Diagnostic System
Number of subjects: 289
Study 35058354 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology assessments following Banff guidelines
Number of subjects: 289
Study 35058690 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 ventilators (higher PTP 300)
Number of subjects: 10
Study 35058690 — intervention group
Group type: COMPARATOR
Intervention: Group 2 ventilators (lower PTP 300)
Number of subjects: 10
Study 35058690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench study with nine ventilators
Number of subjects: 10
Study 35058694 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic ICAD
Number of subjects: 573
Study 35058694 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic ICAD
Number of subjects: 573
Study 35058784 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologically-Based Kinetics (PBK) model for homosalate
Number of subjects: 0
Study 35058882 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid receptor antagonism with mifepristone
Number of subjects: 0
Study 35058882 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35059291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical traditional Korean medical treatment
Number of subjects: 65
Study 35060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizen responders activated by a smartphone application during evening hours (4:00-11:59 pm)
Number of subjects: 438
Study 35060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizen responders activated by a smartphone application during daytime hours (07:00 am-03:59 pm)
Number of subjects: 438
Study 35060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizen responders activated by a smartphone application during nighttime hours (12:00-06:59 am)
Number of subjects: 438
Study 35060479 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccination
Number of subjects: 0
Study 35060784 — intervention group
Group type: EXPERIMENTAL
Intervention: @ctivehip telerehabilitation program (12 weeks duration)
Number of subjects: 71
Study 35060784 — intervention group
Group type: COMPARATOR
Intervention: Traditional care and rehabilitation provided by the Andalusian Public Health Care System (Control)
Number of subjects: 71
Study 35060784 — intervention group
Group type: EXPERIMENTAL
Intervention: @ctivehip telerehabilitation program
Number of subjects: 71
Study 35060907 — intervention group
Group type: EXPERIMENTAL
Intervention: InTSHA intervention (mobile phone-based intervention using WhatsApp, 10 modules conducted weekly)
Number of subjects: 80
Study 35060907 — intervention group
Group type: EXPERIMENTAL
Intervention: InTSHA intervention
Number of subjects: 80
Study 35060907 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study 35060914 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial Ecosystem Therapeutic-2 (MET-2), 3 capsules per day for 8 weeks
Number of subjects: 12
Study 35060914 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial Ecosystem Therapeutic-2 (MET-2)
Number of subjects: 12
Study 35061093 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset COVID-19 infection in neonates
Number of subjects: 176
Study 35061093 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical findings associated with severe disease
Number of subjects: 176
Study 35061093 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory findings
Number of subjects: 176
Study 35061093 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin time above 14 seconds
Number of subjects: 176
Study 35061112 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO with triggered alerts as an add-on to standard care
Number of subjects: 138
Study 35061112 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 138
Study 35061234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 995
Study 35061234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib coadministration with rifampin
Number of subjects: 995
Study 35061234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib coadministration with fluconazole and fluvoxamine, inflammatory skin conditions (psoriasis/AD), and hepatic impairment
Number of subjects: 995
Study 35061234 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian participants
Number of subjects: 995
Study 35061249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 1190
Study 35061509 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe global fatigue at T2 (score ≥ 40/100, EORTC QLQ-C30)
Number of subjects: 5640
Study 35061509 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pretreatment fatigue
Number of subjects: 5640
Study 35061577 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ventilation
Number of subjects: 0
Study 35061769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (defined as known hypertension or use of antihypertensive medication)
Number of subjects: 1138
Study 35062149 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHERA CARING digital platform for emotional and self-management support
Number of subjects: 0
Study 35062926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Prescription Program (FVPP) with high exposure (> 24 months)
Number of subjects: 700
Study 35062926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Prescription Program (FVPP) with moderate exposure (12-24 months)
Number of subjects: 700
Study 35062926 — intervention group
Group type: COMPARATOR
Intervention: Fruit and Vegetable Prescription Program (FVPP) with no previous exposure
Number of subjects: 700
Study 35062967 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline levels of moderate-intensity physical activity
Number of subjects: 762
Study 35062967 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline levels of vigorous-intensity physical activity
Number of subjects: 762
Study 35062967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 762
Study 35062967 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity physical activity
Number of subjects: 762
Study 35062967 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in activity levels across the school year
Number of subjects: 762
Study 35062987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C supplementation (40 mg/kg)
Number of subjects: 30
Study 35063042 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation including high-intensity interval training and resistance training, nutritional support, dietician consultation, medical optimization, duration: at least 4 weeks
Number of subjects: 8
Study 35063223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance methods (MF-BIA, SF-BIA, BIS)
Number of subjects: 62
Study 35063223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance methods (BIS by Matthie)
Number of subjects: 62
Study 35063223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance methods (BIS by Moissl)
Number of subjects: 62
Study 35063223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance methods (all)
Number of subjects: 62
Study 35063223 — intervention group
Group type: COMPARATOR
Intervention: DXA
Number of subjects: 62
Study 35063222 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 639
Study 35063222 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 639
Study 35063229 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte selenium
Number of subjects: 109
Study 35063229 — intervention group
Group type: COMPARATOR
Intervention: Plasma selenium
Number of subjects: 109
Study 35063276 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib maintenance monotherapy (300 mg twice daily)
Number of subjects: 279
Study 35063882 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy
Number of subjects: 957
Study 35063882 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone
Number of subjects: 957
Study 35064012 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG, troponin T (TnT), and transthoracic echocardiography (TTE) acquired by paramedics.
Number of subjects: 253